Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
复制标题
DOI：
10.3851/imp1749
复制
发表时间：
2011
影响因子：
1.2
通讯作者：
Pau AK
中科院分区：
文献类型：
--
作者：
Boyd SD;Maldarelli F;Sereti I;Ouedraogo GL;Rehm CA;Boltz V;Shoemaker D;Pau AK
我们描述了一名HIV感染患者，治疗前对雷特格韦、核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂耐药，最终能够实现病毒抑制。未常规进行治疗前整合酶耐药检测，因为目前认为导致雷特格韦耐药的传播性整合酶突变可忽略不计。我们建议获得治疗前整合酶基因型的患者传播的多类耐药，以创造一个最佳的第一方案，并增加病毒学抑制的机会。
We describe an HIV-infected patient with pre-treatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors, and the ultimate ability to achieve viral suppression. Pre-treatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pre-treatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virologic suppression.